Roxadustat promotes osteoblast differentiation and prevents estrogen deficiency-induced bone loss by stabilizing HIF-1α and activating the Wnt/β-catenin signaling pathway

BACKGROUND: Osteoporosis is a very common skeletal disorder that increases the risk of fractures. However, the treatment of osteoporosis is challenging. Hypoxia-inducible factor-1α (HIF-1α) plays an important role in bone metabolism. Roxadustat is a novel HIF stabilizer, and its effects on bone meta...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Luyao, Li, Afang, Zhu, Li, Gan, Liangying, Zuo, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9124388/
https://www.ncbi.nlm.nih.gov/pubmed/35597989
http://dx.doi.org/10.1186/s13018-022-03162-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9124388/
https://www.ncbi.nlm.nih.gov/pubmed/35597989
http://dx.doi.org/10.1186/s13018-022-03162-w

Ejemplares similares